Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Capital Expenditures (2016 - 2025)

Cytokinetics (CYTK) has disclosed Capital Expenditures for 16 consecutive years, with $34000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures changed N/A to $34000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a N/A change, with the full-year FY2025 number at $2.6 million, down 20.78% from a year prior.
  • Capital Expenditures was $34000.0 for Q4 2025 at Cytokinetics, down from $1.5 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $21.9 million in Q3 2021 to a low of -$3.1 million in Q3 2022.
  • A 5-year average of $3.9 million and a median of $1.8 million in 2024 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 1058.18% in 2024; the steepest drop was 335.15% in 2024.
  • Cytokinetics' Capital Expenditures stood at $17.8 million in 2021, then plummeted by 46.67% to $9.5 million in 2022, then crashed by 99.19% to $77000.0 in 2023, then surged by 3209.09% to $2.5 million in 2024, then crashed by 98.67% to $34000.0 in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Capital Expenditures are $34000.0 (Q4 2025), $1.5 million (Q1 2025), and $2.5 million (Q3 2024).